The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.

Marion SubkleweAriel PerezGloria IacoboniOlaf PenackVeit BückleinLiv JentzschDimitrios MougiakakosGrace JohnsonBrian ArciolaCecilia CarpioViktoria BlumenbergEva HosterLars BullingerFrederick L LockeMichael von Bergwelt-BaildonAndreas MackensenWolfgang BethgePere BarbaMichael D JainMarion Subklewe

Published in: Journal for immunotherapy of cancer (2022)

to CD19 CAR-T. High-risk patients likely benefit from anti-infective prophylaxis and should be closely monitored for potential infections and relapse.

Keyphrases

end stage renal disease
newly diagnosed
prognostic factors
patient reported outcomes